Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Issues Guidance To Promote Domestic Innovation And Facilitate Industry Consolidation

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Before the release of a new five-year plan, China's Ministry of Industry and Information Technology, the Ministry of Health and the State FDA jointly released new guidance Nov. 9 to expedite restructuring China's healthcare industry, a signal of the government's efforts to promote innovation and industry consolidation

You may also be interested in...



China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines

SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China

China Likely To Delay Drug Price Cuts Until Next Year: Good News Or Bad?

SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals

China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics

SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system

Latest News
See All
UsernamePublicRestriction

Register

SC073570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel